Tetraphase Selects SHYFT To Support Data And Analytics For Commercial Launch Readiness

July 18, 2018

By Bio-IT World Staff

July 18, 2018 | SHYFT Analytics announced Tetraphase has selected its platform to support the anticipated commercial launch of eravacycline, its lead antibiotic candidate developed to address multidrug-resistant bacteria. The launch is subject to approval by regulatory authorities. With its scalable cloud platform, SHYFT will empower Tetraphase with novel analytics that provide comprehensive market intelligence and commercial insights to meet commercialization milestones and help drive a successful drug launch.

According to the Centers for Disease and Control (CDC), approximately two million Americans contract infections from antibiotic-resistant bacteria each year. Tetraphase has leveraged its proprietary, fully-synthetic chemistry technology to develop a pipeline of innovative antibiotics with unique profiles that have the potential to improve the treatment of serious bacterial infections.

Eravacycline is currently being developed for the treatment of complicated intra-abdominal infections (cIAI). Pending a decision by the US Food and Drug Administration, Tetraphase plans to launch the broad-spectrum antibiotic in the US later in 2018. As part of that potential launch, Tetraphase will use the Intelligent Platform for Life Sciences to effectively integrate their numerous data sources and create a holistic view of the relevant clinical and commercial information – enabling insights into various areas, including payer needs and the patient journey.

“Addressing the increase in antibiotic resistance relies on effective novel therapies like Tetraphase’s eravacycline,” Zack King, EVP Medidata, President of SHYFT, said in a press release. “A product’s success in this therapeutic area requires a thorough understanding of the market, patients, and unique differentiators. We’re honored to partner with the Tetraphase team on an innovative approach to data analytics to ensure that new and life-changing therapies have the opportunity to thrive in an ever-changing, complex market. This is core to SHYFT’s mission.”